Additional file 1: Table S1. of Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Abstract

Treatment costs according to type of first-line treatment received by patients with EGFR Mut + NSCLC. (DOCX 15 kb